91 related articles for article (PubMed ID: 16494625)
41. Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells.
Bernusso VA; Machado-Neto JA; Pericole FV; Vieira KP; Duarte AS; Traina F; Hansen MD; Olalla Saad ST; Barcellos KS
Biochim Biophys Acta; 2015 Feb; 1853(2):388-95. PubMed ID: 25450971
[TBL] [Abstract][Full Text] [Related]
42. Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.
Snyder DS; McMahon R; Cohen SR; Slovak ML
Am J Hematol; 2004 Feb; 75(2):92-5. PubMed ID: 14755375
[TBL] [Abstract][Full Text] [Related]
43. ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells.
Tamura T; Kong HJ; Tunyaplin C; Tsujimura H; Calame K; Ozato K
Blood; 2003 Dec; 102(13):4547-54. PubMed ID: 12933588
[TBL] [Abstract][Full Text] [Related]
44. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
Al-Ali HK; Heinrich MC; Lange T; Krahl R; Mueller M; Müller C; Niederwieser D; Druker BJ; Deininger MW
Hematol J; 2004; 5(1):55-60. PubMed ID: 14745431
[TBL] [Abstract][Full Text] [Related]
45. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
Ohmine K; Nagai T; Tarumoto T; Miyoshi T; Muroi K; Mano H; Komatsu N; Takaku F; Ozawa K
Stem Cells; 2003; 21(3):315-21. PubMed ID: 12743326
[TBL] [Abstract][Full Text] [Related]
46. Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.
Ernst T; Hoffmann J; Erben P; Hehlmann R; Hochhaus A; Müller MC
Clin Chem Lab Med; 2008; 46(3):318-22. PubMed ID: 18303987
[TBL] [Abstract][Full Text] [Related]
47. Expression of CCL9/MIP-1gamma is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells.
Iotti G; Ferrari-Amorotti G; Rosafio C; Corradini F; Lidonnici MR; Ronchetti M; Bardini M; Zhang Y; Martinez R; Blasi F; Calabretta B
Oncogene; 2007 May; 26(24):3482-91. PubMed ID: 17160016
[TBL] [Abstract][Full Text] [Related]
48. Elevated expression of a subset of interferon inducible genes in primary bone marrow cells expressing p185 Bcr-Abl versus p210 Bcr-Abl by DNA microarray analysis.
Advani AS; Dressman HK; Quiroz M; Taylor GA; Pendergast AM
Leuk Res; 2004 Mar; 28(3):285-94. PubMed ID: 14687624
[TBL] [Abstract][Full Text] [Related]
49. BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs).
Chiorean EG; Dylla SJ; Olsen K; Lenvik T; Soignier Y; Miller JS
Blood; 2003 May; 101(9):3527-33. PubMed ID: 12511422
[TBL] [Abstract][Full Text] [Related]
50. [Effects of bcr/abl fusion gene on expression of beta1 integrin and L-selectin in mouse chronic myeloid leukemia cells].
Wang WL; Shen T; Hui YR; Gu XC; Li RS
Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):337-9. PubMed ID: 12941184
[TBL] [Abstract][Full Text] [Related]
51. The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.
García-Tuñón I; Hernández-Sánchez M; Ordoñez JL; Alonso-Pérez V; Álamo-Quijada M; Benito R; Guerrero C; Hernández-Rivas JM; Sánchez-Martín M
Oncotarget; 2017 Apr; 8(16):26027-26040. PubMed ID: 28212528
[TBL] [Abstract][Full Text] [Related]
52. Expression of p210 bcr/abl increases hematopoietic progenitor cell radiosensitivity.
Santucci MA; Anklesaria P; Laneuville P; Das IJ; Sakakeeny MA; FitzGerald TJ; Greenberger JS
Int J Radiat Oncol Biol Phys; 1993 Aug; 26(5):831-6. PubMed ID: 8344852
[TBL] [Abstract][Full Text] [Related]
53. Global effects of BCR/ABL and TEL/PDGFRbeta expression on the proteome and phosphoproteome: identification of the Rho pathway as a target of BCR/ABL.
Unwin RD; Sternberg DW; Lu Y; Pierce A; Gilliland DG; Whetton AD
J Biol Chem; 2005 Feb; 280(8):6316-26. PubMed ID: 15569670
[TBL] [Abstract][Full Text] [Related]
54. Comparative gene expression profile of p185(Bcr-Abl) versus p210(Bcr-Abl) expressing cells.
Tipping AJ; Melo JV
Leuk Res; 2004 Mar; 28(3):219-20. PubMed ID: 14687613
[No Abstract] [Full Text] [Related]
55. Oral administration of imatinib to P230 BCR/ABL-expressing transgenic mice changes clones with high BCR/ABL complementary DNA expression into those with low expression.
Inami M; Inokuchi K; Yamaguchi H; Nakayama K; Watanabe A; Uchida N; Tanosaki S; Dan K
Int J Hematol; 2006 Nov; 84(4):346-53. PubMed ID: 17118762
[TBL] [Abstract][Full Text] [Related]
56. BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance.
Hickey FB; Cotter TG
J Biol Chem; 2006 Feb; 281(5):2441-50. PubMed ID: 16291747
[TBL] [Abstract][Full Text] [Related]
57. An in vivo and in vitro comparison of the effects of b2-a2 and b3-a2 p210BCR-ABL splice variants on murine 32D cells.
Guinn BA; Evely RS; Walsh V; Gilkes AF; Burnett AK; Mills KI
Leuk Lymphoma; 2000 Apr; 37(3-4):393-404. PubMed ID: 10752991
[TBL] [Abstract][Full Text] [Related]
58. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations.
Pane F; Intrieri M; Quintarelli C; Izzo B; Muccioli GC; Salvatore F
Oncogene; 2002 Dec; 21(56):8652-67. PubMed ID: 12476311
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cells.
Yu W; Sun X; Tang H; Tao Y; Dai Z
Leuk Lymphoma; 2010 Jun; 51(6):1098-107. PubMed ID: 20536348
[TBL] [Abstract][Full Text] [Related]
60. Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R.
Sheng Z; Wang SZ; Green MR
EMBO J; 2009 Apr; 28(7):866-76. PubMed ID: 19229297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
